NCT02715726
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
See it on ClinicalTrials.gov ↗615 people
25%
75%
154 womenmiddle line = equal numbers461 men
- Phase
- PHASE3
- Paid for by
- Sanofi
- Finished
- 2018-08-06
- Health conditions
- Hypercholesterolemia
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 58.6 Years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Asian 100% · American Indian / Alaska Native 0% · Native Hawaiian / Pacific Islander 0% · Black / African American 0% · White 0% · More than one race 0% · Not reported 0%
Women left out
No rules that kept women out were found.
Study titles and rules are shown in their original English.